[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0003386B8 - pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas - Google Patents

pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas

Info

Publication number
BRPI0003386B8
BRPI0003386B8 BRPI0003386A BR0003386A BRPI0003386B8 BR PI0003386 B8 BRPI0003386 B8 BR PI0003386B8 BR PI0003386 A BRPI0003386 A BR PI0003386A BR 0003386 A BR0003386 A BR 0003386A BR PI0003386 B8 BRPI0003386 B8 BR PI0003386B8
Authority
BR
Brazil
Prior art keywords
sub
prodrugs
homo
phosphodiesterases
heterodimeric
Prior art date
Application number
BRPI0003386A
Other languages
English (en)
Other versions
BR0003386A (pt
BRPI0003386B1 (pt
Inventor
Mannochio De Souza Russo Elisa
Freire Torres Russo Valter
Original Assignee
Cristalia Produtos Quim Farmaceuticos Ltda
Ogari De Castro Pacheco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cristalia Produtos Quim Farmaceuticos Ltda, Ogari De Castro Pacheco filed Critical Cristalia Produtos Quim Farmaceuticos Ltda
Priority to BRPI0003386A priority Critical patent/BRPI0003386B8/pt
Priority to DK01953709T priority patent/DK1315729T3/da
Priority to EP01953709A priority patent/EP1315729B1/en
Priority to ES01953709T priority patent/ES2299497T3/es
Priority to US10/362,602 priority patent/US7148350B2/en
Priority to AT01953709T priority patent/ATE383363T1/de
Priority to PCT/BR2001/000096 priority patent/WO2002012241A1/en
Priority to DE60132339T priority patent/DE60132339T2/de
Priority to AU2001276200A priority patent/AU2001276200A1/en
Priority to HK03108868A priority patent/HK1058189A1/xx
Publication of BR0003386A publication Critical patent/BR0003386A/pt
Publication of BRPI0003386B1 publication Critical patent/BRPI0003386B1/pt
Publication of BRPI0003386B8 publication Critical patent/BRPI0003386B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"pró-drogas homodiméricas, heterodiméricas e/ou homo e heteromultiméricas, composições farmacêuticas destas e seus sais, métodos de obtenção destas pró-drogas e seus sais farmacêuticos aceitáveis e aplicação terapêutica no tratamento de doenças ou disfunções mediadas por fosfodiesterases, ou onde a inibição destas enzimas ocasione efeitos terapêuticos desejados". a presente invenção descreve a obtenção de novos compostos, sintetizados na forma de pró-drogas homodiméricas, heterodiméricas e/ou homo e heteromultiméricas, os quais apresentam atividade de inibição de fosofodiesterases, sendo úteis no tratamento de doenças e disfunções mediadas por esta classe de enzimas ou onde a inibição destas enzimas ocasione efeitos terapêuticos desejados. estes compostos, sintetizados como pró-drogas, são ativados pelo organismo através de processos bioquímicos naturais, ativação esta que é efetivada via clivagem de suas pontes de ligação lábeis. a disponibilização das drogas ativas, derivadas destas pró-drogas, se faz de forma natural no organismo influindo positivamente em seus efeitos, aumentando a biodisponibilidade destas drogas ativas, incremento este que é acompanhado de menores efeitos colaterais, devido a menor degradação das drogas ativas pelo metabolismo pré-sistêmico.
BRPI0003386A 2000-08-08 2000-08-08 pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas BRPI0003386B8 (pt)

Priority Applications (10)

Application Number Priority Date Filing Date Title
BRPI0003386A BRPI0003386B8 (pt) 2000-08-08 2000-08-08 pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas
DK01953709T DK1315729T3 (da) 2000-08-08 2001-08-07 Forbindelser i form af homo- eller heterodimere prolægemidler; fremgangsmåder til opnåelse af disse prolægemidler og deres farmaceutiske acceptable salte og anvendelse af forbindelser ved behandling af phosphordiesterease-medierede sygdomme eller ....
EP01953709A EP1315729B1 (en) 2000-08-08 2001-08-07 Compounds in the form of homodimeric or heterodimeric prodrugs; process for obtaining these prodrugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterases-mediated diseases or dysfunction
ES01953709T ES2299497T3 (es) 2000-08-08 2001-08-07 Compuestos en forma de profarmacos homodimericos o heterodimericos, procedimiento para obtenern estos profarmacos y sus sales farmaceuticamente aceptable y uso de los compuestos en el tratamiento de enfermedades o disfuncion mediadas por fosfodiesterasas.
US10/362,602 US7148350B2 (en) 2000-08-08 2001-08-07 Compounds in the form of homodimeric or heterodimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterases-mediated diseases or dysfunction
AT01953709T ATE383363T1 (de) 2000-08-08 2001-08-07 Verbindungen in form homodimerer oder heterodimerer prodrugs; verfahren zur herstellung dieser prodrugs und deren pharmakologisch verträglichen salzen und verwendung von verbindungen in der behandlung von phosphodiesterase vermittelten krankheiten und funktionsstörungen
PCT/BR2001/000096 WO2002012241A1 (en) 2000-08-08 2001-08-07 Compounds in the form of homodimeric, heterodimeric and/or homo and heteromultimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterasis-mediated diseases or dysfunction
DE60132339T DE60132339T2 (de) 2000-08-08 2001-08-07 Verbindungen in form homodimerer oder heterodimerer prodrugs; verfahren zur herstellung dieser prodrugs und deren pharmakologisch verträglichen salzen und verwendung von verbindungen in der behandlung von phosphodiesterase vermittelten krankheiten und funktionsstörungen
AU2001276200A AU2001276200A1 (en) 2000-08-08 2001-08-07 Compounds in the form of homodimeric, heterodimeric and/or homo and heteromultimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterasis-mediated diseases or dysfunction
HK03108868A HK1058189A1 (en) 2000-08-08 2003-12-04 Compounds in the form of homodimetric or heterodimetric prodrugs; process for obtaining these prodrugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterases-mediated diseases or dysfunction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0003386A BRPI0003386B8 (pt) 2000-08-08 2000-08-08 pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas

Publications (3)

Publication Number Publication Date
BR0003386A BR0003386A (pt) 2004-07-06
BRPI0003386B1 BRPI0003386B1 (pt) 2016-10-11
BRPI0003386B8 true BRPI0003386B8 (pt) 2021-05-25

Family

ID=3944849

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0003386A BRPI0003386B8 (pt) 2000-08-08 2000-08-08 pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas

Country Status (10)

Country Link
US (1) US7148350B2 (pt)
EP (1) EP1315729B1 (pt)
AT (1) ATE383363T1 (pt)
AU (1) AU2001276200A1 (pt)
BR (1) BRPI0003386B8 (pt)
DE (1) DE60132339T2 (pt)
DK (1) DK1315729T3 (pt)
ES (1) ES2299497T3 (pt)
HK (1) HK1058189A1 (pt)
WO (1) WO2002012241A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110882A2 (en) * 2005-04-12 2006-10-19 Psivida Inc. Hmgcoa reductase inhibitor codrugs and uses thereof
JP2009503075A (ja) * 2005-08-01 2009-01-29 シヴィダ・インコーポレイテッド ＨＭＧＣｏＡ還元酵素インヒビターコドラッグ及びその使用
JP2009184981A (ja) * 2008-02-07 2009-08-20 Shiseido Co Ltd 抗ｄ−アミノ酸モノクローナル抗体及び、抗ｄ−アミノ酸モノクローナル抗体を用いたｄ−アミノ酸の免疫学的分析方法
WO2015093924A1 (es) * 2013-12-19 2015-06-25 CASTRO ALDRETE, Jorge Issac Vehículo para la administración de compuestos farmacéuticos
CN109658984B (zh) * 2018-12-18 2021-12-03 北京深度制耀科技有限公司 一种信息推荐和信息推荐模型训练方法、相关装置

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4997913A (en) 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
US4863911A (en) 1986-08-04 1989-09-05 University Of Florida Method for treating male sexual dysfunction
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5059603A (en) 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
US5140013A (en) 1989-11-28 1992-08-18 Universite Laval Maleic anhydride derivatives used as conjugation agents of anti-tumor agents on desired carriers
JPH04334377A (ja) 1990-12-31 1992-11-20 Akzo Nv 酸−不安定性リンカー分子
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
IL114520A0 (en) 1994-07-15 1995-11-27 Lepetit Spa Dinucleoside-5',5',-pyrophosphates
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
JP2001527561A (ja) 1997-05-15 2001-12-25 ドラッグ イノベーション アンド デザイン，インコーポレーテッド アシクロビルジエステル誘導体
US6037346A (en) 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6030997A (en) 1998-01-21 2000-02-29 Eilat; Eran Acid labile prodrugs
WO1999059584A1 (en) 1998-05-20 1999-11-25 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
US6124461A (en) 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
US6288234B1 (en) 1998-06-08 2001-09-11 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US6265420B1 (en) 1998-06-23 2001-07-24 Medinox, Inc. Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
US6200591B1 (en) 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
WO2000000199A1 (en) 1998-06-26 2000-01-06 Nastech Pharmaceutical Company, Inc. Nasal delivery of sildenafil citrate
DE19834507A1 (de) 1998-07-31 2000-02-03 Hexal Ag Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
DE19834506A1 (de) 1998-07-31 2000-02-03 Hexal Ag Transmucosales therapeutisches System zur Anwendung von Sildenafil
DE19834505A1 (de) 1998-07-31 2000-02-03 Hexal Ag Transdermales therapeutisches System zur Anwendung von Sildenafil

Also Published As

Publication number Publication date
BR0003386A (pt) 2004-07-06
DE60132339D1 (de) 2008-02-21
US7148350B2 (en) 2006-12-12
EP1315729A4 (en) 2004-07-07
HK1058189A1 (en) 2004-05-07
WO2002012241A8 (en) 2003-12-04
AU2001276200A1 (en) 2002-02-18
WO2002012241A1 (en) 2002-02-14
DE60132339T2 (de) 2008-12-24
BRPI0003386B1 (pt) 2016-10-11
EP1315729A1 (en) 2003-06-04
ATE383363T1 (de) 2008-01-15
ES2299497T3 (es) 2008-06-01
EP1315729B1 (en) 2008-01-09
DK1315729T3 (da) 2008-05-26
US20040106629A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
BR0116468A (pt) Compostos de pirrolina substituìda por indazolila como inibidores de cinase
BR9915883A (pt) Composto, composição farmacêutica, uso de um composto, métodos de tratamento ou de prevenção do distúrbio de agregação de plaqueta, de tratamento ou de prevenção do infarto do miocárdio, derrame trombótico, ataques isquêmicos transitórios e/ou doença vascular periférica e de tratamento ou de prevenção da angina instável ou estável, e, processo para a preparação de um composto
EA200200716A1 (ru) Арилконденсированные азаполициклические соединения
MY130668A (en) Isothiazole derivatives useful as anticancer agents
TR200000837A2 (tr) Anti-kanser bileşimleri hazırlamak için işlem ve ara maddeler.
EA199901014A1 (ru) C-4"-замещенные макролидные производные
WO2002032900A3 (en) Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
ES2193391T3 (es) Antagonistas muscarinicos.
WO2003048164A3 (en) Adenosine a2a receptor antagonists
MA27568A1 (fr) Derives de pyrrolopyrimidine
EA200100412A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
TR200001279T2 (tr) Poli (ADP-riboz) polimeraz ("PARP") inhibitörleri, nevral ve kardiyovasküler doku hasarının tedavisi için yöntemler ve farmasötik bileşimler.
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BR9913319A (pt) Composições e métodos para tratamento de doenças mitocondriais
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
DK0707591T3 (da) Methylphosphonsyreestere, fremgangsmåde til deres fremstilling samt deres anvendelse
BR0206935A (pt) Composto, formulação farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de condições associadas com a inibição da glicogênio sintase quinase-3, e, processo para a preparação de um composto
BR9914998A (pt) Antibióticos macrólidos
AR019496A1 (es) Azalidas de 13 miembros, composiciones farmaceuticas, uso en la preparacion de medicamentos y preparacion de los mismos
ATE268337T1 (de) C11-carbamate von antibakteriellen makroliden
DE60102171D1 (de) Ketolidantibiotika
WO2002079149A3 (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
BRPI0003386B8 (pt) pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas
GT200100232A (es) Derivados de pirimidina.
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos

Legal Events

Date Code Title Description
GLA Others concerning applications: notification of judicial decision
FBOS Technical and formal requirements: other requirements
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: PARA QUE SEJA ACEITA A PETICAO NO 020090057448/RJ DE 10/06/2009 APRESENTE PETICAO DE DESARQUIVAMENTO DO PEDIDO, BEM COMO A RESPECTIVA RETRIBUICAO RELATIVA AO CUMPRIMENTO DE EXIGENCIA, EM VIRTUDE DO DISPOSTO NO ART. 33 UNICO DA LPI.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/10/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/08/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 08/08/2020